• 1
    Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189-199.
  • 2
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292-2302.
  • 3
    Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114: 937-951.
  • 4
    Morel P, Hebbar M, Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia. 1993; 7: 1315-1323.
  • 5
    Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993; 7: 499-508.
  • 6
    Haase D, Fonatsch C, Freund M, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol. 1995; 70: 171-187.
  • 7
    Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005; 90: 1168-1178.
  • 8
    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 9
    Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110: 4385-4395.
  • 10
    Bernasconi P, Klersy C, Boni M, et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia. 2005; 19: 1424-1431.
  • 11
    Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008; 113: 3331-3340.
  • 12
    ISCN. An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N, eds. Basel, Switzerand: S. Karger; 2005.
  • 13
    Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. Am J Hematol. 1994; 46: 270-277.
  • 14
    Pasquali F, Bernasconi P, Casalone R, et al. Pathogenetic significance of “pure” monosomy 7 in myeloproliferative disorders. Analysis of 14 cases. Hum Genet. 1982; 62: 40-51.
  • 15
    Velloso ER, Michaux L, Ferrant A, et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. Br J Haematol. 1996; 92: 574-581.
  • 16
    Brezinova J, Zemanova Z, Ransdorfova S, et al. Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies. Cancer Genet Cytogenet. 2007; 173: 10-16.
  • 17
    Slovak ML, O'Donnell M, Smith DD, Gaal K. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared with −7/del(7q) MDS. Cancer Genet Cytogenet. 2009; 193: 78-85.